Celiac Disease Treatment Market Size & Growth Analysis to 2030

The global celiac disease treatment market size was valued at over USD 650 million in 2024 and projected to grow at a significant CAGR of over 11.5% during the forecast period from 2025 to 2030. The market is experiencing steady growth due to the increasing prevalence of celiac disease worldwide and rising awareness regarding gluten intolerance. Currently, the primary treatment for celiac disease is strict adherence to a lifelong gluten-free diet, driving demand for gluten-free food products and nutritional supplements. However, ongoing research and clinical trials are focusing on pharmaceutical interventions, including enzyme therapies, immune-modulating drugs, and peptide-based therapies, which aim to reduce gluten-induced inflammation and improve patient outcomes. North America and Europe dominate the market due to well-established healthcare infrastructure and higher disease awareness, while the Asia-Pacific region is expected to witness significant growth due to improving diagnostic rates and increasing consumer awareness.

Advancements in diagnostic techniques, such as serological tests and genetic screening, are further driving early detection and treatment adoption. The market also benefits from government initiatives, patient advocacy groups, and research funding supporting celiac disease awareness and therapeutic development. Key players in the industry are investing in novel drug development, including monoclonal antibodies and gluten-degrading enzymes, to provide alternative treatment options. Challenges such as high costs of gluten-free foods, misdiagnosis, and lack of FDA-approved pharmaceutical treatments persist, but continued innovation and increasing consumer demand are expected to drive long-term market expansion.

Market Snapshot:

Market Drivers:

The global celiac disease treatment market is expanding due to several key factors, including the rising prevalence of celiac disease and increasing awareness of gluten-related disorders. With improved diagnostic technologies, more cases are being accurately identified, leading to higher demand for treatment solutions. The growing popularity of gluten-free diets, even among non-celiac individuals, has also boosted market growth, with food companies introducing a wide range of gluten-free products to meet consumer needs. Furthermore, ongoing research and clinical trials are exploring pharmaceutical treatments beyond dietary management, aiming to provide alternative or complementary solutions for patients who struggle with strict gluten-free adherence. North America and Europe currently lead the market due to well-established healthcare systems and strong consumer awareness, while the Asia-Pacific region is expected to witness significant growth due to increasing diagnostic rates and changing dietary habits.

A major development in the market is the progress of Anokion’s ACeD-it trial, which has shown promising clinical data supporting KAN-101 as a potential disease-modifying treatment for celiac disease. Unlike conventional management approaches that rely solely on dietary restrictions, KAN-101 targets the immune system to address the root cause of the disease, offering a novel therapeutic pathway. This breakthrough brings hope for celiac patients seeking more effective treatment options beyond avoiding gluten. Additionally, companies and research institutions worldwide are investing heavily in innovative therapies, including enzyme-based treatments and immune-modulating drugs, to provide better disease management. Despite challenges such as the high cost of gluten-free foods and the lack of FDA-approved pharmaceutical treatments, the continuous progress in research and development is expected to drive long-term market expansion.

Market Trends:

Growing Research on Pharmaceutical Treatments: While a strict gluten-free diet remains the primary treatment for celiac disease, pharmaceutical companies are actively developing alternative therapies. Innovations include immune-modulating drugs, monoclonal antibodies, and gluten-degrading enzymes, which aim to reduce gluten sensitivity or prevent immune system overreaction. Recent clinical trials, such as Anokion’s KAN-101, highlight a shift toward disease-modifying treatments that could transform long-term management.

Advancements in Diagnostic Technologies: Improved diagnostic tools, including genetic testing, serological assays, and biopsy-free detection methods, are enabling earlier and more accurate identification of celiac disease. The development of non-invasive diagnostic techniques is expected to enhance disease monitoring and treatment adherence, driving further market growth.

Expansion of the Gluten-Free Market: With increasing awareness of celiac disease and gluten intolerance, the gluten-free food industry continues to expand. Major food brands and startups are introducing a wide variety of gluten-free alternatives, from bakery products to packaged meals, to cater to both diagnosed celiac patients and health-conscious consumers. The rising availability of these products is supporting market demand.

Increased Investment in Clinical Research: Pharmaceutical companies and research institutions are securing significant investments to explore new therapeutic options. Collaborations between biotech firms, universities, and healthcare organizations are accelerating the discovery of novel drugs and treatment approaches, ensuring steady progress in the field.

Regulatory Support and Patient Advocacy: Governments and healthcare organizations are increasing funding for celiac disease research while patient advocacy groups play a crucial role in spreading awareness. Regulatory bodies are also reviewing emerging drug candidates, which could lead to the first FDA-approved treatment for celiac disease in the coming years.

Market Opportunities:

The global celiac disease treatment market presents vast opportunities, largely driven by advancements in research and the development of innovative therapeutic solutions beyond the traditional gluten-free diet. While strict avoidance of gluten remains the only widely accepted treatment, pharmaceutical companies are actively exploring new avenues such as enzyme therapies, immune-modulating drugs, and therapeutic vaccines to improve patient outcomes. Enzyme-based treatments are particularly promising as they help break down gluten before it can trigger an immune response, offering a potential alternative to a strict lifelong dietary restriction. Additionally, the exploration of anti-inflammatory drugs and biologics aims to minimize intestinal damage caused by autoimmune reactions in celiac patients. As clinical trials progress, these pharmaceutical advancements could lead to the first FDA-approved drug for celiac disease, significantly transforming the market landscape and providing patients with more effective management options.

Another major opportunity lies in the expansion of the gluten-free food industry, which has witnessed tremendous growth due to rising consumer demand. Not only are individuals with celiac disease seeking safer dietary options, but health-conscious consumers are also driving the demand for gluten-free alternatives, expanding the market potential. Recognizing this trend, major food manufacturers are investing in specialized gluten-free production facilities. For example, Arnott’s, a leading food company, recently invested $14 million to upgrade its Marleston manufacturing hub in Adelaide, with the goal of increasing gluten-free sales to 10% of its total biscuit sales. Such initiatives demonstrate the growing commitment of major brands to cater to gluten-intolerant consumers while simultaneously tapping into the broader health-conscious market. With continued investments in both pharmaceutical treatments and gluten-free product innovations, the celiac disease treatment market is expected to experience substantial growth, offering better solutions for patients and greater business opportunities for companies.

Market Insights:

The global celiac disease treatment market is bifurcated into treatment, route of administration, distribution channel, and geography. On the basis of treatment, the vitamins and minerals segment dominated the market with the largest revenue share of over 1/3 of the market, primarily due to the high prevalence of nutrient deficiencies among celiac patients. Since celiac disease damages the small intestine, it impairs nutrient absorption, leading to deficiencies in iron, calcium, vitamin D, vitamin B12, and folic acid. These deficiencies contribute to conditions such as anemia, osteoporosis, and neurological disorders, making supplementation a critical aspect of disease management. Unlike other treatment options that are still under clinical trials or development, vitamins and minerals are widely available, recommended by healthcare providers, and used as a standard part of celiac disease management. The increasing awareness of long-term health complications due to malnutrition further drives the demand for these supplements, ensuring their strong market position.

Additionally, the widespread adoption of vitamin and mineral supplementation is supported by easy accessibility and affordability, compared to newer, developing treatments like gluten-degrading enzymes and immune-modulating drugs. Many celiac patients rely on over-the-counter vitamins or prescribed supplements to compensate for their nutrient loss, ensuring consistent market demand. Moreover, pharmaceutical and nutraceutical companies are expanding their portfolios to include celiac-specific vitamin and mineral formulations, further strengthening this segment. While research on alternative treatments like enzyme-based therapies, symptomatic drugs, and immune-modulating treatments is progressing, vitamins and minerals remain the most established and widely used treatment, securing their dominance in the celiac disease treatment market.

The celiac disease treatment market research report presents the analysis of each segment from 2020 to 2030 considering 2023 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2025 to 2030.

Historical & Forecast Period

• 2020-23 – Historical Year
• 2024 – Base Year
• 2025-2030 – Forecast Period

Market Segmentation:

By Treatment:

• Vitamins & Minerals
• Gluten Degrading Enzymes
• Symptomatic Treatment (Anti-inflammatory Drugs, Antihistamines, Others)
• Others

By Route of Administration:

• Oral
• Parenteral

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis:

Geographically, the North American region dominates the global celiac disease treatment market in 2023, driven by a high prevalence of the disease, well-developed healthcare infrastructure, and strong consumer demand for gluten-free products. In the United States, approximately 1 in 133 individuals suffer from celiac disease, leading to a growing need for effective treatment solutions. This increasing patient population has fueled significant research investments, resulting in the development of new pharmaceutical therapies, enzyme-based treatments, and advanced diagnostic tools. Furthermore, the presence of leading pharmaceutical companies and medical institutions focused on celiac disease research has strengthened the region’s market position. The availability of advanced diagnostic techniques and treatment options, coupled with high healthcare awareness, further contributes to North America’s dominance in this market.

In addition to pharmaceutical advancements, the region has witnessed a surge in the demand for gluten-free food alternatives, driven by both celiac patients and health-conscious consumers. As a result, food manufacturers are actively investing in gluten-free product development and expanding their distribution networks. The increasing awareness of gluten intolerance and dietary preferences has led to supermarkets, restaurants, and food brands offering a wider range of gluten-free options. This shift in consumer behavior has not only propelled the gluten-free food industry but has also strengthened the overall celiac disease treatment market, as dietary management remains a cornerstone of disease control. With continuous product innovation and medical research, North America is expected to maintain its leading position in the Celiac Disease Treatment Market in the coming years.

Competitive Landscape:

Some of the prominent market players operating in the global celiac disease treatment market are Teva Pharmaceutical Industries Ltd., Amgen Inc., Amneal Pharmaceuticals LLC., GLENMARK PHARMACEUTICALS LTD., and Takeda Pharmaceutical Company Limited. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Recent Developments:

• In February 2025, AliveDx filed a 510(k) premarket notification with the U.S. FDA for its MosaiQ AiPlex Celiac Disease microarray. This innovative diagnostic tool is designed to enhance both the accuracy and efficiency of detecting celiac disease.
• Then, in February 2024, Novartis secured FDA approval for Xolair (omalizumab), marking it as the first and only treatment specifically aimed at reducing allergic reactions in individuals aged one and older with IgE-mediated food allergies.

Key Companies:

• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Amneal Pharmaceuticals LLC.
• GLENMARK PHARMACEUTICALS LTD.
• Takeda Pharmaceutical Company Limited.
• Hikma Pharmaceuticals PLC
• Viatris Inc.
• Zydus Pharmaceuticals, Inc.
• Novartis Pharmaceuticals Corporation
• BioLineRx Ltd.

Key Questions Answered by Celiac Disease Treatment Market Report

• Global celiac disease treatment market forecasts from 2025-2030
• Regional market forecasts from 2025-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2025-2030 covering 15 major countries from the regions as mentioned above
• Celiac disease treatment submarket forecasts from 2025-2030 covering the market by treatment, route of administration, distribution channel, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level celiac disease treatment markets from 2025-2030
• Competitive Landscape and market positioning of top 10 players operating in the market